首页> 美国卫生研究院文献>Frontiers in Bioengineering and Biotechnology >Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience
【2h】

Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience

机译:间充质干细胞治疗重度类固醇难治性急性移植物抗宿主病-单中心经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The most effective treatment of steroid refractory acute graft vs. host disease (aGvHD) is not yet established and mesenchymal stem cells (MSC) appear to be a promising therapy for the condition. We report single center case series of three patients, who underwent allogeneic hematopoietic cell transplantation and later developed steroid refractory graft-vs.-host disease, treated with MSC infusions. Two patients achieved complete remission and one patient partial remission of skin and/or gastrointestinal aGvHD. We demonstrated application of MSC for treatment of severe steroid refractory aGvHD is feasible in clinical practice. Detailed description of patient's features and MSC production protocol is crucial for future comparison on efficacy and safety of cell-based therapies. However, for any substantial conclusions regarding efficacy of MSC higher patient numbers will be required.
机译:尚未确定最有效的治疗类固醇难治性急性移植物抗宿主病的方法,间充质干细胞(MSC)似乎是一种有希望的治疗方法。我们报告了三例患者的单中心病例系列,他们接受了同种异体造血细胞移植,后来发生了类固醇难治性移植物抗宿主病,并接受了MSC输注治疗。两名患者的皮肤和/或胃肠道aGvHD完全缓解,一名患者部分缓解。我们证明了将MSC用于治疗严重的类固醇难治性aGvHD在临床实践中是可行的。患者特征和MSC产生方案的详细说明对于将来基于细胞疗法的疗效和安全性比较至关重要。但是,对于有关MSC疗效的任何实质性结论,将需要更高的患者人数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号